

MAP Pharmaceuticals, Inc.
Form 8-K
February 18, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2011

MAP PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)

| | | |
|---|--|--|
| Delaware (State or Other Jurisdiction of Incorporation) | 001-33719 (Commission File Number) | 20-0507047 (IRS Employer Identification No.) |
|---|--|--|

| | |
|---|---------------------|
| 2400 Bayshore Parkway, Suite 200, Mountain View, CA (Address of Principal Executive Offices) | 94043 (Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code: (650) 386-3100

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 16, 2011, Steven A. Elms tendered his resignation as a member and as Chair of the Board of Directors (the "Board") of MAP Pharmaceuticals, Inc. (the "Company"), effective as of February 16, 2011. The resignation of Mr. Elms did not involve a disagreement with the Company.

Also on February 16, 2011, the Board appointed Scott R. Ward, a current member of the Board, to succeed Mr. Elms in the position of Chair.

The Company issued a press release dated February 18, 2011 announcing the foregoing, a copy of which press release is attached hereto as Exhibit 99.1, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| Exhibit No. | Description |
|-------------|---|
| 99.1 | Press Release of MAP Pharmaceuticals, Inc., dated February 18, 2011 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 18, 2011

MAP PHARMACEUTICALS, INC.

By: /s/ Charlene A. Friedman
Name: Charlene A. Friedman
Title: Senior Vice President, General
Counsel and Secretary

INDEX TO EXHIBITS FILED WITH
THE CURRENT REPORT ON FORM 8-K DATED FEBRUARY 18, 2011

| Exhibit | Description |
|---------|---|
| 99.1 | Press Release of MAP Pharmaceuticals, Inc., dated February 18, 2011 |
